Pictet Asset Management Ltd. boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 438.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 491,283 shares of the specialty pharmaceutical company’s stock after acquiring an additional 400,083 shares during the quarter. Pictet Asset Management Ltd. owned 0.97% of Supernus Pharmaceuticals worth $19,651,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SUPN. First Trust Advisors LP bought a new position in shares of Supernus Pharmaceuticals during the third quarter valued at about $2,255,000. Nationwide Fund Advisors grew its stake in shares of Supernus Pharmaceuticals by 240.1% during the third quarter. Nationwide Fund Advisors now owns 242,691 shares of the specialty pharmaceutical company’s stock valued at $9,708,000 after buying an additional 171,341 shares during the last quarter. Alpha Cubed Investments LLC bought a new position in shares of Supernus Pharmaceuticals during the third quarter valued at about $254,000. LS Investment Advisors LLC grew its stake in shares of Supernus Pharmaceuticals by 30.9% during the third quarter. LS Investment Advisors LLC now owns 9,148 shares of the specialty pharmaceutical company’s stock valued at $366,000 after buying an additional 2,162 shares during the last quarter. Finally, Winslow Evans & Crocker Inc. bought a new position in shares of Supernus Pharmaceuticals during the third quarter valued at about $273,000. 96.11% of the stock is currently owned by institutional investors and hedge funds.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of the firm’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock worth $7,223,108 over the last three months. 6.70% of the stock is owned by insiders.

SUPN has been the topic of a number of recent research reports. Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $45.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, September 8th. Stifel Nicolaus reissued a “buy” rating and issued a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Janney Montgomery Scott initiated coverage on Supernus Pharmaceuticals in a research note on Friday, July 14th. They issued a “neutral” rating and a $47.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $49.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 19th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $49.78.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at $42.05 on Monday. The company has a quick ratio of 1.74, a current ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2,131.90, a PE ratio of 36.89, a P/E/G ratio of 1.84 and a beta of 1.30. Supernus Pharmaceuticals, Inc. has a 12 month low of $17.25 and a 12 month high of $50.04.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Shares Bought by Pictet Asset Management Ltd.” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-shares-bought-by-pictet-asset-management-ltd/1682737.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.